Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec;7(6):1032-1038.
doi: 10.3892/mco.2017.1443. Epub 2017 Oct 4.

Clinical significance of atypical squamous cells of undetermined significance after treatment for cervical intraepithelial grade 3 neoplasia: A retrospective single-center cohort study

Toshimichi Onuma  1   2 , Kimihisa Tajima  2 , Kumiko Sato  2 , Katsushige Hattori  2 , Shin Fukuda  2 , Takahiro Tsuji  2 , Yoshio Yoshida  1
Affiliations

Clinical significance of atypical squamous cells of undetermined significance after treatment for cervical intraepithelial grade 3 neoplasia: A retrospective single-center cohort study

Toshimichi Onuma et al. Mol Clin Oncol. 2017 Dec.

Abstract

The aim of the present study was to evaluate the clinical significance of atypical squamous cells of undetermined significance (ASC-US) following cervical conization for cervical intraepithelial neoplasia (CIN) grade 3. This study was a retrospective cohort analysis. The medical records of women treated with conization for CIN 2-3 were reviewed and 142 patients with CIN 3 who had been diagnosed using the conization specimens were selected. The mean follow-up period after conization was 41.8 months. Cytological abnormalities after conization were observed in 19.0% of the patients and consisted of ASC-US (13.4%) and worse than low-grade squamous intraepithelial lesion (LSIL; 5.6%). Recurrence was defined as a diagnosis worse than CIN 2, and the recurrence rate was 29.6% among patients with abnormal cytology. The recurrence rate was 15.7% in the ASC-US group and 71.4% in the worse than LSIL group. There was no significant difference in the time of initial identification of abnormal cytology after treatment between the worse than LSIL and the ASC-US groups (P=0.054). However, the ASC-US group had a significantly better cumulative recurrence-free rate compared with the worse than LSIL group (P<0.05). Women with ASC-US following treatment for CIN appear to be at a relatively high risk. Regarding the risk stratification of women following treatment for CIN, if surveillance cytology shows ASC-US, immediate colposcopy is recommended, along with long-term follow-up.

Keywords: atypical squamous cells of undetermined significance; cervical intraepithelial neoplasia grade 3; conization; follow-up cytology; recurrence.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Cumulative recurrence-free rate. Kaplan-Meier survival curves with log-rank tests, with patient status at the time of the last follow-up visit, were used to compare the cumulative recurrence-free rates among the normal, ASC-US and worse than LSIL groups. NILM, negative for intraepithelial lesion or malignancy; ASC-US, atypical squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesion.
See this image and copyright information in PMC

References

    1. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, Solomon D, Wentzensen N, Lawson HW. 2012 ASCCP Consensus Guidelines Conference: 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013;121:829–846. doi: 10.1097/AOG.0b013e3182883a34. - DOI - PubMed
    1. van der Heijden E, Lopes AD, Bryant A, Bekkers R, Galaal K. Follow-up strategies after treatment (large loop excision of the transformation zone (LLETZ)) for cervical intraepithelial neoplasia (CIN): Impact of human papillomavirus (HPV) test. Cochrane Database Syst Rev. 2015;1:CD010757. - PMC - PubMed
    1. American College of Obstetricians and Gynecologists: Practice Bulletin No. 140: Management of abnormal cervical cancer screening test results and cervical cancer precursors. Obstet Gynecol. 2013;122:1338–1367. doi: 10.1097/01.AOG.0000438960.31355.9e. - DOI - PubMed
    1. Hanley SJ, Fujita H, Tamakoshi A, Dong P, Sakuragi N. Challenges in breast and cervical cancer control in Japan. Lancet Oncol. 2016;17:e372. doi: 10.1016/S1470-2045(16)30411-9. - DOI - PubMed
    1. Melnikow J, Kulasingam S, Slee C, Helms LJ, Kuppermann M, Birch S, McGahan CE, Coldman A, Chan BK, Sawaya GF. Surveillance after treatment for cervical intraepithelial neoplasia: Outcomes, costs, and cost-effectiveness. Obstet Gynecol. 2010;116:1158–1170. doi: 10.1097/AOG.0b013e3181f88e72. - DOI - PubMed